Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1985 3
1986 2
1987 2
1988 3
1989 3
1990 6
1991 5
1992 5
1993 7
1994 8
1995 2
1996 4
1997 7
1998 11
1999 22
2000 18
2001 17
2002 21
2003 29
2004 46
2005 51
2006 56
2007 68
2008 71
2009 81
2010 95
2011 128
2012 180
2013 168
2014 179
2015 178
2016 188
2017 194
2018 236
2019 289
2020 344
2021 346
2022 384
2023 428
2024 132

Text availability

Article attribute

Article type

Publication date

Search Results

3,611 results

Results by year

Filters applied: . Clear all
Page 1
VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway.
Lee C, Chen R, Sun G, Liu X, Lin X, He C, Xing L, Liu L, Jensen LD, Kumar A, Langer HF, Ren X, Zhang J, Huang L, Yin X, Kim J, Zhu J, Huang G, Li J, Lu W, Chen W, Liu J, Hu J, Sun Q, Lu W, Fang L, Wang S, Kuang H, Zhang Y, Tian G, Mi J, Kang BA, Narazaki M, Prodeus A, Schoonjans L, Ornitz DM, Gariepy J, Eelen G, Dewerchin M, Yang Y, Ou JS, Mora A, Yao J, Zhao C, Liu Y, Carmeliet P, Cao Y, Li X. Lee C, et al. Among authors: xing l. Signal Transduct Target Ther. 2023 Aug 18;8(1):305. doi: 10.1038/s41392-023-01539-9. Signal Transduct Target Ther. 2023. PMID: 37591843 Free PMC article.
Biology-guided deep learning predicts prognosis and cancer immunotherapy response.
Jiang Y, Zhang Z, Wang W, Huang W, Chen C, Xi S, Ahmad MU, Ren Y, Sang S, Xie J, Wang JY, Xiong W, Li T, Han Z, Yuan Q, Xu Y, Xing L, Poultsides GA, Li G, Li R. Jiang Y, et al. Among authors: xing l. Nat Commun. 2023 Aug 23;14(1):5135. doi: 10.1038/s41467-023-40890-x. Nat Commun. 2023. PMID: 37612313 Free PMC article.
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.
Lu S, Zhang W, Wu L, Wang W, Zhang P; Neotorch Investigators; Fang W, Xing W, Chen Q, Yang L, Mei J, Tan L, Sun X, Xu S, Hu X, Yu G, Yu D, Yang N, Chen Y, Shan J, Xing L, Tian H, Zhang X, Zhou M, Fang H, Wu G, Liu Y, Ye M, Cao L, Jiang J, Li X, Zhu L, Li D, Kang M, Zhong A, Chen K, Wu N, Sun Q, Ma H, Cai K, Wang C, Lin G, Zhu K, Zhang Y, Zhang X, Hu H, Zhang W, Chen J, Yang Z, Hang X, Hu J, Huang Y, Zhang Z, Zhang L, Zhang L, Liu L, Lin D, Zhang J, Chen G, Li Y, Zhu L, Wang W, Yu W, Cao D, Keegan P, Yao S. Lu S, et al. Among authors: xing l. JAMA. 2024 Jan 16;331(3):201-211. doi: 10.1001/jama.2023.24735. JAMA. 2024. PMID: 38227033 Clinical Trial.
Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.
He J, Ouyang N, Guo X, Sun G, Li Z, Mu J, Wang DW, Qiao L, Xing L, Ren G, Zhao C, Yang R, Yuan Z, Wang C, Shi C, Liu S, Miao W, Li G, Chen CS, Sun Y; CRHCP Study Group. He J, et al. Among authors: xing l. Lancet. 2023 Mar 18;401(10380):928-938. doi: 10.1016/S0140-6736(22)02603-4. Epub 2023 Mar 2. Lancet. 2023. PMID: 36871573 Clinical Trial.
Identification of High-Risk Coronary Lesions by 3-Vessel Optical Coherence Tomography.
Jiang S, Fang C, Xu X, Xing L, Sun S, Peng C, Yin Y, Lei F, Wang Y, Li L, Chen Y, Pei X, Jia R, Tang C, Li S, Li S, Yu H, Chen T, Tan J, Liu X, Hou J, Dai J, Yu B. Jiang S, et al. Among authors: xing l. J Am Coll Cardiol. 2023 Apr 4;81(13):1217-1230. doi: 10.1016/j.jacc.2023.01.030. Epub 2023 Mar 14. J Am Coll Cardiol. 2023. PMID: 36925409
3,611 results